The estimated Net Worth of Martin A. Lehr is at least $592 mil dollars as of 21 February 2023. Mr Lehr owns over 5,823 units of Centrexion Therapeutics stock worth over $341,760 and over the last 3 years he sold CNTX stock worth over $0. In addition, he makes $250,000 as Co-Founder e CEO & Director at Centrexion Therapeutics.
Sign up
Mr Lehr CNTX stock SEC Form 4 insiders trading
Mr has made over 10 trades of the Centrexion Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,823 units of CNTX stock worth $4,891 on 21 February 2023.
The largest trade he's ever made was buying 20,000 units of Centrexion Therapeutics stock on 16 December 2022 worth over $14,800. On average, Mr trades about 7,163 units every 37 days since 2021. As of 21 February 2023 he still owns at least 159,701 units of Centrexion Therapeutics stock.
You can see the complete history of Mr Lehr stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Martin A. Lehr biography
Martin A. Lehr is the Co-Founder, CEO & Director at Centrexion Therapeutics.
What is the salary of Mr Lehr?
As the Co-Founder e CEO & Director of Centrexion Therapeutics, the total compensation of Mr Lehr at Centrexion Therapeutics is $250,000. There are 1 executives at Centrexion Therapeutics getting paid more, with Jennifer Minai-Azary having the highest compensation of $404,331.
How old is Mr Lehr?
Mr Lehr is 37, he's been the Co-Founder e CEO & Director of Centrexion Therapeutics since . There are 5 older and no younger executives at Centrexion Therapeutics. The oldest executive at Centrexion Therapeutics Corporation is Dr. Evan G. Dick, 69, who is the Sr. VP of R&D.
What's Mr Lehr's mailing address?
Martin's mailing address filed with the SEC is 2001 MARKET STREET, SUITE 3915, UNIT #15, PHILADELPHIA, PA, 19103.
Insiders trading at Centrexion Therapeutics
Over the last 3 years, insiders at Centrexion Therapeutics have traded over $0 worth of Centrexion Therapeutics stock and bought 152,118 units worth $245,330 . The most active insiders traders include Richard J Berman, Martin A. Lehr, eLinda West. On average, Centrexion Therapeutics executives and independent directors trade stock every 32 days with the average trade being worth of $21,702. The most recent stock trade was executed by Martin A. Lehr on 21 February 2023, trading 5,823 units of CNTX stock currently worth $4,891.
What does Centrexion Therapeutics do?
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
What does Centrexion Therapeutics's logo look like?
Complete history of Mr Lehr stock trades at Centrexion Therapeutics
Centrexion Therapeutics executives and stock owners
Centrexion Therapeutics executives and other stock owners filed with the SEC include:
-
Jennifer Minai-Azary,
CFO & Treasurer -
Martin A. Lehr,
Co-Founder, CEO & Director -
Dr. William F. Rencher Ph.D.,
Head of CMC & Regulatory -
Dr. Tarek Sahmoud M.D., Ph.D.,
Chief Medical Officer -
Elizabeth Nemchik CPA,
Controller -
Christopher Beck M.B.A.,
Sr. VP of Operations -
Eileen Kittrick CPA,
Controller -
Dr. Evan G. Dick,
Sr. VP of R&D -
Alex C. Levit Esq.,
Chief Legal Officer & Corp. Sec. -
Dr. Felix Kim Ph.D.,
Co-founder & Chair of Scientific Advisory Board -
Luke Nathaniel Walker,
Director -
Karen L. Smith,
Director -
Jennifer Lynn Minai Azary,
Chief Financial Officer -
William F. Rencher,
-
Evan G. Dick,
-
Martin A. Lehr,
Chief Executive Officer -
Alex C. Levit,
Chief Legal Officer, Corp. Sec -
Philip W. Kantoff,
Director -
Jennifer Evans Stacey,
Director -
Linda West,
Director -
Richard J Berman,
Director -
Tarek Sahmoud,
Chief Medical Officer -
Ullmann Claudio Dansky,
Chief Medical Officer